In a newly published systematic review the proof of effect on infant colic was
further strengthened for L. reuteri Protectis. The review evaluated 17 studies
of different treatments of infant colic, whereof L. reuteri Protectis was the
only probiotic. Only one other product was deemed effective. Simethicone, a drug
often prescribed for colic, was shown to have no effect.
Prior to the new review four meta-analyses, evaluating different probiotics as
well as non-probiotic treatments, have come to the same conclusion; that L.
reuteri Protectis is effective in colic, especially in breastfed and mixed fed
infants. In the new, fifth review, with 6 studies on L. reuteri Protectis
included, the proof was further strengthened.
”The new meta-analysis once again confirms our position as the number one
treatment for infants with colic. Today health care professionals around the
world can be totally reassured that they are suggesting an effective treatment
when recommending BioGaia ProTectis drops to their patients”, says Peter
Rothschild, President, BioGaia.
The systematic review and meta-analysis was published online by researchers
Tracey Harb and colleagues at University of Queensland, Australia, in Journal of
Pediatric Gastroenterology and Nutrition 14 December 2015.
Latest press releases from BioGaia
2016-01-08 BioGaia’s subsidiary IBT has US IND open and Swedish CTA¹ approved
for clinical study
2015-12-01 BioGaia makes further investments in MetaboGen
2015-10-26 BioGaia signs exclusive agreement in Sri Lanka
BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 11 January 2016, 11:00
am CET.
For additional information please contact
Peter Rothschild, President, BioGaia: +46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
